BMY Stock - Bristol-Myers Squibb Co

BMY Stock Chart

BMY Profile

Bristol-Myers Squibb Company operates globally in the biopharmaceutical sector, engaging in the discovery, development, licensing, manufacturing, and marketing of a diverse range of therapeutic products. Its portfolio spans treatments for hematology, oncology, cardiovascular diseases, immunology, fibrotic disorders, neuroscience, and COVID-19. Key products include Revlimid for multiple myeloma, Eliquis for stroke prevention and deep vein thrombosis/pulmonary embolism, Opdivo for cancer immunotherapy, and Pomalyst/Imnovid for multiple myeloma patients.

The company also offers a lineup including Orencia for reheumatoid arthrittis and psoriatic arthritis, Sprycel for chronic myeloid leukemia, Yervoy for advanced melanoma, Abraxane for chemotherapy, Reblozyl for beta thalassemia-related anemia, and Empliciti for multiple myeloma treatment. Bristol-Myers Squibb's product range extends to therapies such as Zeposia for multiple sclerosis, Breyanzi for large B-cell lymphoma, Inrebic for myelofibrosis, and Onureg for acute myeloid leukemia.

Founded in 1887 and headquartered in New York, New York, Bristol-Myers Squibb sells its products through wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies worldwide. Formerly known as Bristol-Myers Company, the company remains dedicated to advancing healthcare through innovative therapies across a broad spectrum of medical needs.

BMY Revenue Chart

BMY Earnings

Analyst Ratings